A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Autoimmune disorders; Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 01 Mar 2016 New trial record